½ÃÀ庸°í¼­
»óǰÄÚµå
1754036

ÄÚ°ñÀÌ ¹æÁö Ä¡·á ½ÃÀå º¸°í¼­ : µð¹ÙÀ̽º À¯Çü, À¯Åë ä³Î, Áö¿ªº°(2025-2033³â)

Anti-Snoring Treatment Market Report by Device Type (Mandibular Advancement Devices, Tongue Stabilizing Devices, Continuous Positive Airway Pressure Devices, and Others), Distribution Channel, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ÄÚ°ñÀÌ ¹æÁö Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³â 17¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ÀÌ ½ÃÀåÀÌ 2033³â±îÁö 34¾ï ´Þ·¯¿¡ ´ÞÇØ 2025³âºÎÅÍ 2033³â±îÁö 7.54%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

ÄÚ°ñÀÌ´Â °³ÀÎÀÇ ÄÚ¿Í ÀÔ¿¡¼­ µé¸®´Â ½Ã²ô·¯¿î È£Èí ¼Ò¸®·Î ¸ñ±¸¸ÛÀÇ ¿¬ºÎÁ¶Á÷ÀÇ Áøµ¿À¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÄÚ°ñÀÌ Ä¡·á¿¡´Â ¼ö¼úÀ̳ª Áö¼ÓÀû ¾ç¾ÐÈ£Èí¿ä¹ý(CPAP)ÀÌ »ç¿ëµÇ¸ç, CPAP´Â ÄÚ¿Í ÀÔ¿¡ ¸¶½ºÅ©¸¦ Âø¿ëÇϰí Ä౸¸Û¿¡ ÀÏÁ¤ÇÑ °ø±â È帧À» °ø±ÞÇÏ´Â ±â°è¿¡ ºÎÂøÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ Ã¼Áß À¯Áö, ÄÚ¸·Èû ¿ÏÈ­, ¼ö¸é ÀÚ¼¼ º¯°æ, ¾ËÄÚ¿Ã ¹× ÁøÁ¤Á¦ ÇÇÇÏ±â µî »ýȰ½À°ü °³¼±À¸·Î Ä¡·áÇÒ ¼öµµ ÀÖ½À´Ï´Ù.

ÄÚ°ñÀÌ ¹æÁö Ä¡·á ½ÃÀå µ¿Çâ:

ÄÚ°ñÀÌ ¹æÁö Ä¡·á¸¦ Áö¿øÇÏ´Â ÀåºñÀÇ ±â¼úÀû Áøº¸°¡ Áõ°¡ÇÏ´Â °ÍÀº ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ Àå±âÀûÀÎ ÄÚ°ñÀÌ´Â ÇÇ·Î, ½ÉÀ帶ºñ, °íÇ÷¾Ð, ³úÁ¹Áß, Á¦2Çü ´ç´¢º´, Ç÷Áß »ê¼Ò ³óµµ ÀúÇÏ µîÀÇ ¹ßº´ À§ÇèÀ» ³ôÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ Å« ÄÚ°ñÀÌ¿Í ÀæÀº ÄÚ°ñÀÌ´Â ¼ö¸é¹«È£ÈíÁõ ÁõÈıºÀÇ Â¡ÈÄ Áß ÇϳªÀ̸ç, ¼ö¸é Áß È£ÈíÀÌ ¾è°Å³ª ¸ØÃß´Â °ÍÀ» Ư¡À¸·Î ÇÏ´Â ¸¸¼ºÁúȯÀÔ´Ï´Ù. ¼ö¸é¹«È£ÈíÁõÈıºÀº ¼ö¸é Áß È£ÈíÀÌ ¾è¾ÆÁö°Å³ª È£ÈíÀÌ ¸ØÃß´Â ¸¸¼ºÁúȯÀ¸·Î ³ì³»Àå, ¾Ï, ÀÎÁöÀå¾Ö, ÇൿÀå¾Ö µîÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¸é¹«È£ÈíÁõ ȯÀÚ´Â ¿îÀü Àû¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àֱ⠶§¹®¿¡ ÀÚµ¿Â÷ »ç°íÀÇ À§Ç輺ÀÌ ³ô¾ÆÁý´Ï´Ù. ±× °á°ú, ÄÚ°ñÀÌ Ä¡·á¸¦ À§ÇÑ ÄÚ°ñÀÌ ¹æÁö ¾Û, Çൿ ¿ä¹ý, Ä¡°ú Àåºñ, Çô ¾ÈÁ¤±â(TSD), ÅÎ ÀüÁø ÀåÄ¡(JAD)¶ó°íµµ ¾Ë·ÁÁø ÇÏ¾Ç ÀüÁø ÀåÄ¡(MAD)ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÂ½Ä »ýȰ ½À°ü, °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü, ´ã¹è ¹× ¾ËÄÚ¿Ã ¼Òºñ Áõ°¡, ´ëÁßÀÇ ¼ö¸é Àå¾Ö À¯º´·ü Áõ°¡ µîÀÇ ¿äÀÎÀÌ ½ÃÀå Àü¸ÁÀ» ¹à°Ô ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â?
  • ÄÚ°ñÀÌ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ¿¹»ó ¼ºÀå·ü(2025-2033³â)Àº?
  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • COVID-19°¡ ÄÚ°ñÀÌ Ä¡·áÁ¦ ¼¼°è ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀåÄ¡ À¯Çüº° ºÐ·ù´Â?
  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀå À¯Åë ä³Îº° ºÐ·ù´Â?
  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀå ÁÖ¿ä Áö¿ªÀº?
  • ÄÚ°ñÀÌ ¹æÁö Ä¡·á ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÄÚ°ñÀÌ ¹æÁö Ä¡·á ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : µð¹ÙÀ̽º À¯Çüº°

  • ÇÏ¾Ç ÀüÁø ÀåÄ¡(MAD)
  • Çô ¾ÈÁ¤ ÀåÄ¡(TSD)
  • Áö¼Ó±âµµ¾ç¾Ð(CPAP) ÀåÄ¡
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Airway Management Inc.
    • Apnea Sciences Corporation
    • Fisher & Paykel Healthcare Corporation Limited
    • Koninklijke Philips N.V.
    • MEDiTAS Ltd.
    • Medtronic plc
    • Mitsui Chemicals Inc.
    • ResMed Inc.
    • Rotech Healthcare Inc.
    • SomnoMed
    • The Pure Sleep Company
    • Tomed GmbH
ksm

The global anti-snoring treatment market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.54% during 2025-2033.

Snoring refers to a noisy breathing sound coming through the nose or mouth of an individual, which is caused by the vibration of the soft tissues of the throat. It is medically treated using surgery or continuous positive airway pressure (CPAP), wherein a mask is worn over the nose or mouth and attached to a machine for delivering a constant flow of air into the nostrils. It can also be cured via lifestyle changes, such as maintaining body weight, relieving the nasal obstruction, changing sleep positions, and avoiding alcohol and sedating medications.

Anti-Snoring Treatment Market Trends:

Rising technological advancements in devices that support anti-snoring treatment represent one of the key factors positively influencing the market. Moreover, long-term snoring increases the risk of developing fatigue, heart attacks, hypertension, stroke, type 2 diabetes, and decreased blood oxygen levels. Besides this, loud and frequent snoring is one of the signs of sleep apnea, which is a chronic condition characterized by shallow breaths or pauses in breathing during sleep. This condition can lead to glaucoma, cancer, and cognitive and behavioral disorders. In addition, people with sleep apnea have an increased threat of motor vehicle accidents as it can affect driving fitness. Consequently, there is a rise in the usage of anti-snoring apps, behavioral therapies, dental devices, tongue stabilizing devices (TSD), and mandibular advancing devices (MAD), also known as jaw advancing devices (JAD), to treat snoring, which is fueling the market growth. Furthermore, factors like sedentary lifestyles, unhealthy dietary habits, increasing tobacco and alcohol consumption, and the rising prevalence of sleep disorders among the masses are projected to create a positive outlook for the market.

Key Market Segmentation:

Breakup by Device Type:

  • Mandibular Advancement Devices (MAD)
  • Tongue Stabilizing Devices (TSD)
  • Continuous Positive Airway Pressure (CPAP) Devices
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Airway Management Inc., Apnea Sciences Corporation, Fisher & Paykel Healthcare Corporation Limited, Koninklijke Philips N.V., MEDiTAS Ltd., Medtronic plc, Mitsui Chemicals Inc., ResMed Inc., Rotech Healthcare Inc., SomnoMed, The Pure Sleep Company and Tomed GmbH.

Key Questions Answered in This Report

  • 1.How big is the global anti-snoring treatment market?
  • 2.What is the expected growth rate of the global anti-snoring treatment market during 2025-2033?
  • 3.What are the key factors driving the global anti-snoring treatment market?
  • 4.What has been the impact of COVID-19 on the global anti-snoring treatment market?
  • 5.What is the breakup of the global anti-snoring treatment market based on the device type?
  • 6.What is the breakup of the global anti-snoring treatment market based on the distribution channel?
  • 7.What are the key regions in the global anti-snoring treatment market?
  • 8.Who are the key players/companies in the global anti-snoring treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Snoring Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Device Type

  • 6.1 Mandibular Advancement Devices (MAD)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Tongue Stabilizing Devices (TSD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Continuous Positive Airway Pressure (CPAP) Devices
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Airway Management Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Apnea Sciences Corporation
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Fisher & Paykel Healthcare Corporation Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Koninklijke Philips N.V.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 MEDiTAS Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Medtronic plc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Mitsui Chemicals Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 ResMed Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Rotech Healthcare Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 SomnoMed
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
    • 13.3.11 The Pure Sleep Company
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
    • 13.3.12 Tomed GmbH
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦